House Bill 258 Seeks To Force Health Care Providers to Tell Patients If They Have Dense Breast Tissue
Approximately 10 million women have high breast density in the United States and there is currently no FDA-approved treatment for this condition. For more information about breast density please visit www.areyoudense.org
Recently, House Bill 258 advanced to the senate and proposes that health care providers would be required to tell patients if they have dense breast tissue and to consider further cancer screenings.
The proposed notice reads:
“Your mammogram indicates that you have dense breast tissue. Dense breast tissue is common and is found in as many as half of all women.
However, dense breast tissue can make it more difficult to fully and accurately evaluate your mammogram and detect early signs of possible cancer in the breast.
You might benefit from additional professionally recognized forms of cancer screening examinations, depending on your personal risk factors and family history.
This information is being provided to inform and encourage you to discuss your dense breast tissue and other breast cancer risk factors with your physician or health care provider.
Together, you can decide which screening options are best and most effective for you. A copy of your mammography report has been sent to your physician and health care provider.
Please contact them if you have any questions or concerns about this notice.”
President and CEO of Seattle, WA based Atossa Genetics (NasdaqCM: ATOS), Dr. Steven Quay, commented on this subject recently, “The presence of dense breast tissue can make it more difficult to evaluate the results of a mammogram because dense breast tissue is comprised of less fat and more stromal tissue which appears white on a mammogram. Cancer also appears white and tumors are therefore often hidden or masked by the dense tissue. Breast density is also associated with an increased risk of breast cancer. Although numerous states have recently enacted laws requiring that patients be notified of breast density, there is no federal standard and approximately 20 states still do not require that information about density be conveyed to the patient. We believe woman have the right to receive this important health information and we applaud the pending federal legislation. In addition, the provisions in the legislation that require expansion of programs and research activities related to breast density should improve diagnosis capabilities and accelerate treatments for this major breast cancer risk factor; which is one of only a few risk factors that can actually be modified.” Atossa is developing the drug Endoxifen for tamoxifen-refractory breast cancer patients, the treatment of mammographic breast density and other breast conditions. Atossa’s proprietary Endoxifen is being developed as an oral form as well as a topical solution, like a lotion, that can be applied directly to the breast. Atossa recently completed a Phase 1 study of its oral and topical Endoxifen and reported that all objectives of that study were successfully met. A Phase 2 study will be conducted at Stockholm South General Hospital in Sweden and will be led by principal investigator Dr. Per Hall, M.D., Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet.
To learn about the interesting work that Seattle, WA based biotech firm Atossa Genetics (NasdaqGM: ATOS) is doing in breast cancer treatment please visit the Vista Partners ATOS Company Dedicated Page.